基本信息
浏览量:61
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Since 2001, I have advanced my overall career from PhD student (Italy, Europe), to postdoc (Houston TX, USA), to senior researcher (Finland, Europe, Faculty of Medicine) and finally to tenure-track assistant professor (Finland, Europe, Faculty of Pharmacy). I have successfully worked in several different countries, cultures and environments. I have significantly contributed to approximately 70 peer-reviewed publications (only 4 of which are with my PhD supervisor) and created 10 patents, one of which belongs solely to my laboratory (IVTLab). I have served as an expert abstracts reviewer for the American Society of Gene and Cell Therapy Meeting on the Adenovirus and Other DNA Viruses panel (2013) as well as for Immunotherapy (2014) and Cancer-Oncolytic Viruses (2015), highlighting the broad and recognized knowledge that I have gained in the field of gene therapy. As testimony of my excellent work, this year I received the Outstanding New Investigator Award from the European Society of Gene and Cell Therapy in The Hague, Netherlands.
Since September 2012, I am serving as tenure-track Asst. Professor at the Faculty of Pharmacy, University of Helsinki, and as group leader of the ImmunoViroTherapy Lab (www.ivtlab.org) at the Centre for Drug Research (www.cdr.fi). I am responsible for creating and managing this research group and for initiating and implementing a new line of research and teaching at the Faculty of Pharmacy.
My research has always exceeded the state-of-art of the field at that moment. I was the first scientist to provide evidence that adenoviral vectors trigger part of their immune response through TLRs (Cerullo et al. Mol Ther 2007). I was among the first researchers to hypothesize and demonstrate that oncolytic adenoviruses act by eliciting a tumor- specific immune response (Cerullo et al. Cancer Res).
Nowadays, my laboratory is the first in the field that has developed a customisable and personalised anti-cancer oncolytic vaccine.
研究兴趣
论文共 309 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Thomas G. P. Gruenewald,Sophie Postel-Vinay,Robert T. Nakayama,Noah E. Berlow, Andrea Bolzicco,Vincenzo Cerullo,Josephine K. Dermawan,Anna Maria Frezza,Antoine Italiano,Jia Xiang Jin,Francois Le Loarer, Javier Martin-Broto,
CLINICAL CANCER RESEARCHno. 6 (2024): 1079-1092
Heidi Harjunpää, Riku Somermäki, Guillem Saldo Rubio,Manlio Fusciello,Sara Feola,Imrul Faisal, Anni I Nieminen, Liang Wang, Marc Llort Asens, Hongxia Zhao,Ove Eriksson,Vincenzo Cerullo,
Oncoimmunologyno. 1 (2024): 2369373-2369373
Salvatore Russo,Sara Feola,Michaela Feodoroff,Jacopo Chiaro,Gabriella Antignani,Manlio Fusciello, Federica D’Alessio,Firas Hamdan,Teijo Pellinen, Riikka Mölsä,Lorella Tripodi,Lucio Pastore,
Molecular Therapy: Oncologyno. 1 (2024): 200766-200766
Sara Feola,Firas Hamdan,Salvatore Russo,Jacopo Chiaro,Manlio Fusciello,Michaela Feodoroff,Gabriella Antignani, Federica D'Alessio, Riikka Molsa, Virpi Stigzelius, Paolo Bottega,Sari Pesonen,
JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 3 (2024)
Sara Feola,Firas Hamdan,Salvatore Russo,Jacopo Chiaro,Manlio Fusciello,Michaela Feodoroff,Gabriella Antignani, Federica D'Alessio, Riikka Mölsä, Virpi Stigzelius, Paolo Bottega,Sari Pesonen,
Journal for immunotherapy of cancerno. 3 (2024)
International journal of biological macromoleculesno. Pt 1 (2024): 129926-129926
HELIYONno. 3 (2024): e24599-e24599
crossref(2023)
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn